Tolbutamide is a sulfonylurea-type oral hypoglycemic agent whose action is
terminated by hydroxylation of the tolylsulfonyl methyl moiety catalyzed by
cytochrome P-450 (CYP) enzymes of the human CYP2C subfamily. Although most
studies have implicated CYP2C9 as the exclusive catalyst of hepatic tolbut
amide hydroxylation in humans, there is evidence that other CYP2C enzymes (
e.g., CYP2C19) may also participate. To that end, we used an immunochemical
approach to assess the role of individual CYP2Cs in microsomal tolbutamide
metabolism. Polyclonal antibodies were raised to CYP2C9 purified from huma
n liver, and were then back-adsorbed against recombinant CYP2C19 coupled to
a solid-phase support. Western blotting revealed that the absorbed antihum
an CYP2C9 preparation reacted with only recombinant CYP2C9 and the correspo
nding native protein in hepatic microsomes, and no longer recognized CYP2C1
9 and CYP2C8. Monospecific anti-CYP2C9 not only retained the ability to inh
ibit CYP2C9-catalyzed reactions, as evidenced by its marked (90%) inhibitio
n of diclofenac 4'-hydroxylation by purified CYP2C9 and by human liver micr
osomes, but also exhibited metabolic specificity, as indicated by its negli
gible (< 15%) inhibitory effect on S-mephenytoin 4'-hydroxylation by purifi
ed CYP2C19 or hepatic microsomes containing CYP2C19. Monospecific anti-CYP2
C9 was also found to inhibit rates of tolbutamide hydroxylation by 93 +/- 4
and 78 +/- 6% in CYP2C19-deficient and CYP2C19-containing human liver micr
osomes, respectively. Taken together, our results indicate that both CYP2C9
and CYP2C19 are involved in tolbutamide hydroxylation by human liver micro
somes, and that CYP2C19 underlies at least 14 to 22% of tolbutamide metabol
ism. Although expression of CYP2C19 in human liver is less than that of CYP
2C9, it may play an important role in tolbutamide disposition in subjects e
xpressing either high levels of CYP2C19 or a catalytically deficient CYP2C9
enzyme.